Because of the impact generics can have on patient health, generic manufacturers and service providers have made cost savings and improved adherence central to their mission and drug development efforts.
When it comes to generics, an increasingly crowded marketplace continues to upend expectations for sales and profit margins for all segments of the generic supply chain.
The Association for Accessible Medicines and the National Association of Chain Drug Stores are lobbying Congress and the White House for a change in the Centers for Medicare and Medicaid Services’ policy on reimbursement for biosimilar medicines
The Association for Accessible Medicines CEO, Chip Davis, discusses the savings that generics bring to the healthcare system and how competition can help keep the savings coming.
On a per-share basis, the San Francisco-based company reported net income of $4.33. Earnings, adjusted for one-time gains and costs, were $3.41 per share.
The antiretroviral HIV-1 treatment had U.S. sales of roughly $113 million for the 12 months ended Dec. 31, 2017, according to IQVIA data. Roughly 1.1 million patients in America live with HIV.